Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Leishmaniasis

Leishmaniasis is a disease caused by protozoan parasites that belong to the genus Leishmania and is transmitted by the bite of certain species of sand fly, including flies in the genus Lutzomyia in the New World and Phlebotomus in the Old World. The disease was named in 1901 for the Scottish pathologist William Boog Leishman. This disease is also known as Leichmaniosis, Leishmaniose, leishmaniose, and formerly, Orient Boils, Baghdad Boil, kala azar, black fever, sandfly disease, Dum-Dum fever or espundia.Most forms of the disease are transmissible only from animals , but some can be spread between humans. Human infection is caused by about 21 of 30 species that infect mammals. These include the L. donovani complex with three species ; the L. mexicana complex with 3 main species ; L. tropica; L. major; L. aethiopica; and the subgenus Viannia with four main species braziliensis, L. guyanensis, L. panamensis, and L. peruviana). The different species are morphologically indistinguishable, but they can be differentiated by isoenzyme analysis, DNA sequence analysis, or monoclonal antibodies. Visceral leishmaniasis is a severe form in which the parasites have migrated to the vital organs. (From the Wikpedia article Leishmaniasis.)

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Recent Publications on Leishmaniasis:

Pubmed Logo
Structure of cyclophilin from Leishmania donovani bound to cyclosporin at 2.6 A resolution: correlation between structure and thermodynamic data.
Drug development against Leishmania donovani, the pathogen that causes...
20th November, 2009
Crystallography and Molecular Biology Division, Saha Institute of Nuclear Acta Crystallogr D Biol Crystallogr. 2009 Nov 1;65(Pt 11):1187-1195. Epub
DOI Direct Link
Asymptomatic Leishmania infantum infection in a traditionally non-endemic area of North-western Italy (Piemonte region).
The prevalence of Leishmania infantum specific antibodies and asymptomatic...
20th November, 2009
Department of Clinical and Biological Sciences, University of Torino, J Clin Microbiol. 2009 Nov 18.
DOI Direct Link
Enhanced Susceptibility to Leishmania Infection in Resistant Mice in the Absence of Immediate Early Response Gene X-1.
Immediate early response gene X-1 (IEX-1) is a stress-inducible gene...
20th November, 2009
Wellman Center for Photomedicine, Massachusetts General Hospital, J Immunol. 2009 Nov 18.
DOI Direct Link
[Multifocal cutaneous leishmaniasis due to Leishmania infantum under adalimumab therapy.]
Immediate early response gene X-1 (IEX-1) is a stress-inducible gene...
18th November, 2009
Service de dermatologie, hopital Henri-Mondor, 51, avenue du Ann Dermatol Venereol. 2009 Nov;136(11):815-6. Epub 2009 Oct 9.
DOI Direct Link
The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
Miltefosine is currently marketed for treatment of skin metastasis of...
18th November, 2009
Department of Pharmacology, Toxicology, and Pharmacy, University of Eur J Pharmacol. 2009 Nov 13.
DOI Direct Link

View more research publications.

Press Releases About Leishmaniasis:

BioPortfolio Logo
New Consortium to Develop Drugs for Neglected Tropical Diseases 17th August, 2009
LEIDEN, The Netherlands, August 17 /PRNewswire/ -- A new consortium has been formed to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis,
IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis 22nd January, 2009 IDRI
SEATTLE, Jan. 22 /PRNewswire/ -- IDRI (Infectious Disease Research Institute) announced it has granted the Instituto Butantan, a Brazilian biomedical research institution, an exclusive license in
Max Planck Society Awards Exclusive License to Dafra Pharma R&D to Develop a Drug Against Leishmaniasis 16th July, 2008
TURNHOUT, Belgium, July 16 /PRNewswire/ -- Max Planck Innovation, the technology transfer agency of the Max Planck Society based in Munich, Germany and Dafra Pharma R&D, a Belgian research company
Institute for OneWorld Health Completes Patient Enrollment, Treatment In 1st January, 1970 Institute Of One World
Institute for OneWorld Health Completes Patient Enrollment, Treatment In India for Largest Phase III Clinical Trial for Visceral Leishmaniasis (Kala Azar) San Francisco, Calif. – May 18

BioNews Results for Leishmaniasis:

RSS Logo
BioPortfolio Logo
The Antituberculosis Drug Pyrazinamide Affects the Course of Cutaneous Leishmaniasis In Vivo and Increases Activation of Macrophages and Dendritic Cells
MDLinx:  Nov 20 2009 11:06AM Matching: leishmaniasis
Chembio Reports Third Quarter 2009 Results
Pharmacy Choice:  Nov 5 2009 5:40AM Matching: leishmaniasis
Medical News: New Insight In The Fight Against The Leishmania Parasite
Medical News Today:  Oct 29 2009 2:32PM Matching: leishmaniasis
New Insight In The Fight Against The Leishmania Parasite
Medical News Today:  Oct 29 2009 10:59AM Matching: leishmaniasis
Study Gives New Insight in the Fight Against the Leishmania Parasite
MedIndia:  Oct 25 2009 7:07AM Matching: leishmaniasis
Promote your company here: BioNewsCast - Press Release Distribution

View more news.

Leishmaniasis Patents:

USPTO Logo
US Patent No.Title
7576066 Nucleic acid compositions for stimulating immune responses
7592010 Albumin fusion proteins
7592147 Modulation of IL-2 production by T-bet
7595038 Methods of treatment using antibodies to follistatin-3
7595060 Yeast-antigen compositions methods of making the same

View more patents.

Companies working in the area of Leishmaniasis from Bioportfolio's Biocorporate database :

BioPortfolio Logo
Company Name

Astralis Ltd.

In January 2004, Astralis Ltd received its first patent from the United States Patent Office. This achievement has resulted from the quality and focus of our therapeutic research and development....
www.astralisltd.com/        View full profile
Thumbshot

InBios International, Inc.

InBios International, Inc. is a medical diagnostic company that specializes in developing, manufacturing and marketing medical diagnostic tests for the detection of infectious diseases. Since its...
www.inbios.com/        View full profile
Thumbshot

LICA Pharmaceuticals A/S

LICA Pharmaceuticals and Walter Reed Army Institute of Research, US Army, have entered into a joint research and development agreement on further development of LICA's antimalarial drug candidate ...
www.licapharma.com/        View full profile
Thumbshot

View more Leishmaniasis related companies.

BioPortfolio Ltd. offers e-mail and postal lists for Leishmaniasis scientists - we have details of around 1401 individuals working on Leishmaniasis .


This page has been viewed 583 times
Recent Search Terms used to find this page: Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2009 Apr 15 2 CD004834. Review | leishmaniasis companies | research going in seattle on leishmania | Cellular and humoral responses against Leishmania virulence factors in healed Cutaneous.. | latest publications on leishmania | leishmaniasis research | leishmania meeting | leishmaniasis | leishmania R D | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Leishmaniasis across BioPortfolio, or for Leishmaniasis Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.